Behind the science
Who needs to make their move against RSV?
For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV. We commissioned a new global survey and the results reveal a concerning reality.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.















